Industrial Trend - Industry Total Size
4
Insights
- Biotechnology and Pharmaceuticals generate more sales by total volume
- Life Sciences Tools and Servicea have the most profitable enetrprises
- Pharmaceuticals generate the most cash on the most consistent basis
4/34
Industrial Trend - Profitability
5
Insights
- Life Science Tools and Sciences have steady profitability trends
- Pharmaceuticals are have positive trends in respect to marginal profits
5/34
Concentration and Competition Intensity - Total Revenue
6
-There are many competitors with relatively the same amount of revenue however Thermo Fisher and Iqvia holdings make up much of the market.
- There has recently been an increase in revenue for competitors who are barely visible in past years
6/34
Concentration and Competition Intensity (Pharma) - Total Revenue
7
- Pharma is dominated by a few big players
- J&J and Merck capture over 50% of market
7/34
Concentration and Competition Intensity - Total Revenue
8
- Biotech has a few key players but many smaller competitors probably due to niche research or specialty services
8/34
Supply Chain Map - Revenue
11
Revenue at BMS is highest in Biotech and relativey low in actual drug sales
11/34
12
Most profitable with biotech segment and least profitable with drug retail
12/34
13
Biotech outdoes every other part of their supply chain in regards to profits
13/34
Revenue vs. Cost
15
China, UK, and USA companies all have relatively similar ratios of cost to revenue. The big difference is that the US and UK scale way higher than China.
15/34
Profit vs. Cost - Operating Income
16
Chinese companies make more operating income per total dollar spent probably due to cheap resources and less stringent regulations.
16/34
Operating Margin vs. Revenue
18
Most high-revenue companies have similar operating margins in the low positive range compared to companies with little revenue who are deep in the negative probably due to high initial costs.
18/34
Return on Assets vs. Liability Asset Ratio
19
Biotech companies with lower liability to asset ratios generally operate more efficiently
19/34
Enterprise Ranking - Marginal Revenue
21
Few outliers while the majority hover around the same range
21/34
KPI Examination
22
Healthy looking KPIs especially in profitability. Some weaknesses may be holding on to inventory to long.
22/34
Enterprise Comparison - Total Revenue
23
BMS dominates on total revenue compared to big competitors
23/34
Enterprise Comparison - Profits
24
Pfizer is the most profitable while Moderna is by far the weakest
24/34
Enterprise Trend - Size
25
2021 created crazy spikes in sales most likely due to covid but then seem to return to a relative level of normality
25/34
Enterprise Trend - Size
26
BMS operates on a lot of debt and has fewer assets most likely because of high reliance on research-based operations which can look less valuable on a balance sheet compared to inventory-based companies.
26/34
SCDATA
Update
